Background Patients with chronic obstructive pulmonary disease (COPD) have few options
for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have …

Background: β 2-Agonists andcorticosteroids or theophylline can interact to produce
beneficialeffects on airway function in asthma, but this has not been establishedin COPD …

Despite substantial evidence regarding the benefits of combined use of inhaled
corticosteroids and long-acting β2-agonists in asthma, such evidence remains limited for …

Background: TORCH (Towards a Revolution in COPD Health) is an international
multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone …

Rationale: Cardiovascular drugs may improve survival in chronic obstructive pulmonary
disease (COPD). However, previous studies did not account for major sources of bias, and …

Background: Chronic obstructive pulmonary disease (COPD) is a syndrome of chronic
progressive airflow limitation which occurs as a result of chronic inflammation of the airways …

Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …

Background QVA149 is an inhaled fixed-dose combination therapy under development for
the treatment of chronic obstructive pulmonary disease (COPD). It combines indacaterol (a …

Background Evidence for management of asthma comes from closely monitored efficacy
trials done in highly selected patient groups. There is a need for randomised trials that are …

Objective The aim of these studies (NCT01957163; NCT02119286) was to evaluate the
efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone …